Pharma has a $300B problem—and it’s not just about patents. It’s about time.
In the U.S., the patent system doesn’t merely grant exclusivity; it also tries to compensate for delays outside a drugmaker’s control. That’s where two concepts—patent term ad…

Pharma executives don’t lose deals because they missed a clinical readout.
They lose them because they missed a patent map.
Eurasia—often treated as a “later” market—has become a high-stakes chessboard where drug patents, regulatory exclusivities, and …

Pharmaceutical patent strategy is often treated like a binary choice: fight, settle, or walk away.
But in 2026, that mindset is expensive.
The real advantage belongs to teams that can separate winning portfolios from “expensive archives”—patents that l…

The clock is already ticking. Most “market access” teams are just showing up after the race has started.
In pharma, timing isn’t a soft skill—it’s the business model.
Drug patent cliffs, exclusivity windows, and payer contracting cycles don’t wait for …

Before you launch: the hidden risk in every “sure thing” pharma product
In pharma, optimism is expensive.
You can have the right molecule, the right clinical data, the right manufacturing plan—and still get blindsided by a single patent, a single regul…

Pharma procurement teams are sitting on a blind spot—and it’s costing them leverage.
If you buy drugs, you already know the drill: negotiate price, pressure suppliers, validate quality, and keep formularies compliant. But there’s a quieter, higher-impa…

Drug patents in Asia-Pacific: the protection you think you have vs. the protection you actually get
If you work in pharma—whether you’re licensing, investing, or planning launches—there’s a quiet trap hiding in plain sight: “patent term” is not the sam…

Drug patent expiry dates aren’t just legal milestones—they’re commercial deadlines. And most companies treat them like back-office trivia instead of a growth strategy.
Here’s the agitation: when the market is moving, “we’ll revisit this later” is how y…

Sell the line before the patent breaks. That’s the uncomfortable truth many solid-dose equipment suppliers learn only after the market has already moved.
In generic expansion, timing isn’t a marketing tactic—it’s the difference between being the vendor…

The impact of Lyrica (pregabalin) on liver function is a topic of concern for individuals taking the medication. Lyrica is… https://www.Drugchatter.com/chat/26609/how-does-lyrica-affect-liver-function/